We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+42.07%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$223M
AUM Growth
+$42.5M
Cap. Flow
+$1.52M
Cap. Flow %
0.68%
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
1
Reduced
1
Closed
–

Top Buys

1
AMRN
Amarin Corp
AMRN
+$7.11M
2
BHVN icon
Biohaven
BHVN
+$6.36M

Top Sells

1
CYTK icon
Cytokinetics
CYTK
+$11.9M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INVA icon
1
Innoviva
INVA
$1.6B
$56.3M 25.25%
2,816,022
– –
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$635M
$53.6M 24.07%
15,919,435
– –
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$43M 19.29%
303,151
– –
CYTK icon
4
Cytokinetics
CYTK
$10.9B
$25.2M 11.3%
396,357
-192,000
-33% -$11.9M
AMRN
5
Amarin Corp
AMRN
$292M
$23.4M 10.48%
1,673,395
+430,868
+35% +$7.11M
LNTH icon
6
Lantheus
LNTH
$7B
$12.1M 5.42%
181,450
– –
BHVN icon
7
Biohaven
BHVN
$2.32B
$5.79M 2.6%
+513,184
New +$6.36M
REGN icon
8
Regeneron Pharmaceuticals
REGN
$70.9B
$3.23M 1.45%
4,190
– –
VOR icon
9
Vor Biopharma
VOR
$980M
$332K 0.15%
25,399
– –

Similar funds

DWA
Dougherty Wealth Advisers Wayzata, Minnesota $158M AUM 18.41% 1-Year Est. Return
4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
RA
RiverTree Advisors Winter Park, Florida $158M AUM 5.18% 1-Year Est. Return
FI
FWG Investments Lexington, Kentucky $157M AUM 15.2% 1-Year Est. Return
CC
Corsicana & Co Corsicana, Texas $158M AUM
PWA
Providence Wealth Advisors Frankfort, Illinois $157M AUM 29.27% 1-Year Est. Return

Sarissa Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Sarissa Capital Management held 9 positions worth $223M, up 24% from $180M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management's Q4 2025 filing shows 1 new, 1 increased and 1 reduced positions. Its largest new stake was Biohaven: 513,184 shares worth $5.79M. The largest sale was Cytokinetics, an estimated $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sarissa Capital Management's largest Q4 2025 buy was Biohaven: 513,184 shares worth $5.79M.
  • Sarissa Capital Management added most to Amarin Corp in Q4 2025, an estimated $7.11M increase.
  • Sarissa Capital Management's biggest Q4 2025 reduction was Cytokinetics, cutting an estimated $11.9M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $223M portfolio in Q4 2025.
  • Sarissa Capital Management opened 1 new position and closed 0 in Q4 2025.
  • Sarissa Capital Management's portfolio value rose 24% quarter-over-quarter to $223M.

Based on Sarissa Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.